Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
CVS Health has announced expanded insurance coverage for two of Eli Lilly’s weight management drugs. Consequently, the move will significantly widen patient access. Millions of Americans rely on CVS for their pharmacy benefits, making this, therefore, a consequential shift. Starting…
Eli Lilly may be getting closer to putting a weight loss pill on pharmacy shelves. The company recently announced strong results from a large Phase 3 trial of orforglipron. It’s an experimental daily pill designed to work like injectable GLP-1…
The weight-loss medicine market is facing a major shift today. A major pharmaceutical company secured federal approval for a new pill recently. Consequently, the Wegovy pill represents the first cleared oral option. Another competing firm secured approval for Foundayo shortly…
The national regulatory agency recently authorized a groundbreaking medication called Foundayo. This vital green light gives Eli Lilly a powerful new tool in the competitive weight management sector. Unlike previous treatments, Foundayo gives patients a simple oral option. Consequently, this…
Eli Lilly recently introduced a new daily pill called Foundayo to help adults manage their weight. This medication offers a fresh option for those living with obesity or overweight conditions. Clinical trials show that patients taking the highest dose lost…
The FDA just gave the official green light to Eli Lilly’s brand-new weight-loss pill, Foundayo. This highly anticipated approval kicks off a massive, high-stakes rivalry with Novo Nordisk, the company behind the widely popular drug Wegovy. For months, everyone has…
The weight loss landscape is changing fast. If you hate needles, you finally have something exciting to anticipate. The FDA officially approved a daily semaglutide pill in December 2025. Building on that momentum, experts expect Eli Lilly to launch orforglipron…
Structure Therapeutics just dropped some thrilling news about its new daily weight-loss pill, aleniglipron. During a recent mid-stage trial, patients taking the 180 mg dose shed up to 16.3% of their body weight over 44 weeks. To put that into…
Novo Nordisk launched a new oral semaglutide tablet recently. This convenient pill generated surprisingly strong market demand right away. Consequently, financial experts raised their sales forecasts to nearly 2.8 billion dollars. The oral format clearly solves a major problem for…